S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
Critical asset just had biggest fall on record (Ad)
Best Buy reports lower 4Q sales and profits as shoppers remain cautious
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
Critical asset just had biggest fall on record (Ad)
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
From Hometown Hero to Franchise Partner — 3 Celebrities Collaborating With Their Hometown Brands
S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
Critical asset just had biggest fall on record (Ad)
Best Buy reports lower 4Q sales and profits as shoppers remain cautious
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
Critical asset just had biggest fall on record (Ad)
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
From Hometown Hero to Franchise Partner — 3 Celebrities Collaborating With Their Hometown Brands
S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
Critical asset just had biggest fall on record (Ad)
Best Buy reports lower 4Q sales and profits as shoppers remain cautious
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
Critical asset just had biggest fall on record (Ad)
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
From Hometown Hero to Franchise Partner — 3 Celebrities Collaborating With Their Hometown Brands
S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
Critical asset just had biggest fall on record (Ad)
Best Buy reports lower 4Q sales and profits as shoppers remain cautious
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
Critical asset just had biggest fall on record (Ad)
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
From Hometown Hero to Franchise Partner — 3 Celebrities Collaborating With Their Hometown Brands
NASDAQ:PSNL

Personalis (PSNL) Stock Price, News & Analysis

$1.55
+0.09 (+6.16%)
(As of 02/29/2024 ET)
Today's Range
$1.31
$1.63
50-Day Range
$1.15
$2.35
52-Week Range
$0.89
$3.27
Volume
811,845 shs
Average Volume
352,764 shs
Market Capitalization
$76.00 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.50

Personalis MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
254.8% Upside
$5.50 Price Target
Short Interest
Healthy
2.38% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.66
Upright™ Environmental Score
News Sentiment
0.79mentions of Personalis in the last 14 days
Based on 11 Articles This Week
Insider Trading
Selling Shares
$20,710 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.15) to ($1.57) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.40 out of 5 stars

Medical Sector

118th out of 958 stocks

Medical Laboratories Industry

7th out of 21 stocks


PSNL stock logo

About Personalis Stock (NASDAQ:PSNL)

Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test to optimize therapy selection and match patients to clinical trials; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities. The company also provides ACE platform for clinical and therapeutic applications, such as neoantigen prediction, biomarker identification, and novel drug target selection. It serves pharmaceutical, biopharmaceutical, diagnostic testing, and biotechnology companies; healthcare providers; universities; non-profits; and government entities. The company was incorporated in 2011 and is headquartered in Fremont, California.

PSNL Stock Price History

PSNL Stock News Headlines

Personalis, Inc. (PSNL)
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Personalis: Q4 Earnings Insights
What Wall Street expects from Personalis's earnings
Personalis (PSNL) Set to Announce Quarterly Earnings on Wednesday
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Personalis, ClearNote Health Join Hands To Advance Epigenomic Technology
Personalis Expects Q4 Revenue To Grow 18%
BTIG Keeps Their Buy Rating on Personalis (PSNL)
East Bay cancer test company to shed another 65 jobs
See More Headlines
Receive PSNL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Personalis and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/04/2021
Today
2/29/2024
Next Earnings (Estimated)
5/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medical laboratories
Sub-Industry
N/A
Current Symbol
NASDAQ:PSNL
Fax
N/A
Employees
395
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.50
High Stock Price Target
$7.50
Low Stock Price Target
$3.50
Potential Upside/Downside
+254.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-113,320,000.00
Net Margins
-159.91%
Pretax Margin
-159.79%

Debt

Sales & Book Value

Annual Sales
$65.05 million
Book Value
$4.75 per share

Miscellaneous

Free Float
45,354,000
Market Cap
$76.00 million
Optionable
Optionable
Beta
1.93
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Christopher M. Hall (Age 55)
    President, CEO & Director
    Comp: $506.39k
  • Mr. Aaron L. TachibanaMr. Aaron L. Tachibana (Age 63)
    CFO & COO
    Comp: $569.6k
  • Dr. Richard Chen M.D. (Age 53)
    M.S., Executive VP of R&D and Chief Medical Officer
    Comp: $584.17k
  • Dr. Russ B. Altman M.D.
    Ph.D., Co-Founder and Member of Clinical & Scientific Advisory Board
  • Dr. Euan A. Ashley DPHIL (Age 52)
    FRCP, M.D., Ph.D., Co-Founder and Member of Clinical & Scientific Advisory Board
  • Dr. Michael P. Snyder Ph.D.
    Co-Founder and Member of Clinical & Scientific Advisory Board
  • Mr. Stephen M. Moore J.D. (Age 51)
    VP, General Counsel & Corporate Secretary
  • Mr. Michael J Fitzpatrick
    Vice President of Worldwide Sales
  • Dr. Christian Haudenschild Ph.D.
    Senior Vice President of Genomic Laboratory Operations
  • Mr. Stephane Mouradian Ph.D.
    Senior Vice President of Business Development














PSNL Stock Analysis - Frequently Asked Questions

Should I buy or sell Personalis stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Personalis in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PSNL shares.
View PSNL analyst ratings
or view top-rated stocks.

What is Personalis' stock price target for 2024?

2 brokerages have issued 12 month price objectives for Personalis' shares. Their PSNL share price targets range from $3.50 to $7.50. On average, they expect the company's stock price to reach $5.50 in the next twelve months. This suggests a possible upside of 254.8% from the stock's current price.
View analysts price targets for PSNL
or view top-rated stocks among Wall Street analysts.

How have PSNL shares performed in 2024?

Personalis' stock was trading at $2.10 at the beginning of 2024. Since then, PSNL stock has decreased by 26.2% and is now trading at $1.55.
View the best growth stocks for 2024 here
.

When is Personalis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our PSNL earnings forecast
.

How were Personalis' earnings last quarter?

Personalis, Inc. (NASDAQ:PSNL) posted its quarterly earnings data on Thursday, November, 4th. The company reported ($0.40) EPS for the quarter, hitting the consensus estimate of ($0.40). The firm earned $22.26 million during the quarter, compared to analysts' expectations of $22.20 million. Personalis had a negative net margin of 159.91% and a negative trailing twelve-month return on equity of 58.66%. During the same period in the prior year, the company posted ($0.27) EPS.

What ETF holds Personalis' stock ?

ARK Genomic Revolution ETF holds 5,920,884 shares of PSNL stock, representing 0.56% of its portfolio.

What guidance has Personalis issued on next quarter's earnings?

Personalis updated its first quarter 2024 earnings guidance on Wednesday, February, 28th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $18.0 million-$19.0 million, compared to the consensus revenue estimate of $19.1 million.

What is John West's approval rating as Personalis' CEO?

17 employees have rated Personalis Chief Executive Officer John West on Glassdoor.com. John West has an approval rating of 75% among the company's employees.

What other stocks do shareholders of Personalis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Personalis investors own include Enphase Energy (ENPH), Pfizer (PFE), Dynavax Technologies (DVAX), QUALCOMM (QCOM), Advanced Micro Devices (AMD), NIO (NIO), NVIDIA (NVDA), Viking Therapeutics (VKTX), AbbVie (ABBV) and

When did Personalis IPO?

(PSNL) raised $100 million in an IPO on Thursday, June 20th 2019. The company issued 6,700,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen and Company acted as the underwriters for the IPO and Oppenheimer was co-manager.

Who are Personalis' major shareholders?

Personalis' stock is owned by a variety of retail and institutional investors. Top institutional investors include ARK Investment Management LLC (13.61%), GSA Capital Partners LLP (0.81%), Bruce & Co. Inc. (0.61%), Bridgeway Capital Management LLC (0.26%), Green Alpha Advisors LLC (0.24%) and Dimensional Fund Advisors LP (0.22%). Insiders that own company stock include Aaron Tachibana, Christopher M Hall, John Stephen West, Lightspeed Venture Partners Se, Richard Chen and Stephen Michael Moore.
View institutional ownership trends
.

How do I buy shares of Personalis?

Shares of PSNL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PSNL) was last updated on 3/1/2024 by MarketBeat.com Staff